These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Effect of clofibrate on lipid metabolism in streptozotocin diabetic rats. Cayen MN; Dubuc J; Dvornik D Proc Soc Exp Biol Med; 1975 Mar; 148(3):752-7. PubMed ID: 165533 [TBL] [Abstract][Full Text] [Related]
5. Clofibrate and clofibric acid: comparison of the metabolic disposition in rats and dogs. Cayen MN; Ferdinandi ES; Greselin E; Robinson WT; Dvornik D J Pharmacol Exp Ther; 1977 Jan; 200(1):33-43. PubMed ID: 833760 [TBL] [Abstract][Full Text] [Related]
6. [Research regarding the action of a derivative of the clofibric acid series on lipid metabolism]. Filip M; Păduraru I; Hriscu A; Neacşu R; Dănilă G; Filip F Rev Med Chir Soc Med Nat Iasi; 1987; 91(2):341-5. PubMed ID: 3685700 [No Abstract] [Full Text] [Related]
7. Hypolipaemic activity of 1-(theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (etofylline clofibrate) and its analogues in normolipaemic rats. Ginocchio AV; Metz G Arzneimittelforschung; 1980; 30(11b):2032-4. PubMed ID: 7194054 [TBL] [Abstract][Full Text] [Related]
8. [Action of etofibrate, clofibrate and nicotinic acid on the metabolism of lipids in normolipemic rats. Short term effects and method of action]. Priego JG; Piña M; Armijo M; Sunkel C; Maroto ML Arch Farmacol Toxicol; 1979 Apr; 5(1):29-42. PubMed ID: 38756 [No Abstract] [Full Text] [Related]
9. Effect of clofibrate on plasma lipids of rat and rabbit. Byers SO; Friedman M Atherosclerosis; 1970; 11(3):373-82. PubMed ID: 5433083 [No Abstract] [Full Text] [Related]
10. Anticholesterolemic effect of 3,4-di(OH)-phenylpropionic amides in high-cholesterol fed rats. Kim SJ; Bok SH; Lee S; Kim HJ; Lee MK; Park YB; Choi MS Toxicol Appl Pharmacol; 2005 Oct; 208(1):29-36. PubMed ID: 16164959 [TBL] [Abstract][Full Text] [Related]
11. Lipid lowering influence of ethyl p-chlorophenoxyisobutyrate in liver of rats fed high fat diets. Kokatnur MG; Malcom GT Metabolism; 1970 Feb; 19(2):120-8. PubMed ID: 5410942 [No Abstract] [Full Text] [Related]
12. In vivo and in vitro peroxisome proliferation properties of selected clofibrate analogues in the rat. Structure-activity relationships. Esbenshade TA; Kamanna VS; Newman HA; Tortorella V; Witiak DT; Feller DR Biochem Pharmacol; 1990 Sep; 40(6):1263-74. PubMed ID: 2403380 [TBL] [Abstract][Full Text] [Related]
13. The effects of tiadenol, clofibrate and clofibride on bile composition in the rat. Rozé C; Cuchet P; Souchard M; Vaille C; Debray C Eur J Pharmacol; 1977 May; 43(1):57-64. PubMed ID: 862664 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic study and bioavailability of three marketed compounds releasing p-chlorophenoxyisobutyric acid (CPIB) in volunteers. Harvengt C; Desager JP Int J Clin Pharmacol Biopharm; 1976 Sep; 14(2):113-8. PubMed ID: 1002348 [TBL] [Abstract][Full Text] [Related]
15. The effects of probucol and clofibrate alone and in combination on hepatic cholesterol metabolism in the male rat. Shand JH; West DW Biochim Biophys Acta; 1995 Mar; 1255(2):123-30. PubMed ID: 7696326 [TBL] [Abstract][Full Text] [Related]
16. HYPOLIPEMIA AND HEPATOMEGALY FROM ETHYL CHLOROPHENOXYISOBUTYRATE (CPIB) IN THE RAT. BEST MM; DUNCAN CH J Lab Clin Med; 1964 Oct; 64():634-42. PubMed ID: 14233152 [No Abstract] [Full Text] [Related]
17. Effect of SaH 42-348, an analog of clofibrate, on lipid metabolism in rats. Kritchevsky D; Tepper SA Arzneimittelforschung; 1973 Jun; 23(6):858-9. PubMed ID: 4740771 [No Abstract] [Full Text] [Related]